Extracellular vesicles in cancer nanomedicine

Tarasov, Vadim V.; Svistunov, Andrey; Chubarev, Vladimir N.; Dostdar, Samira A.; Соколов, А. В.; Brzecka, Anna; Sukocheva, Olga; Neganova, Margarita E.; Клочков, С. Г.; Somasundaram, Siva G; Kirkland, Cecil E; Aliev, Gjumrakch

doi:10.1016/j.semcancer.2019.08.017

Cited by 75 publications

(62 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Being natural carriers of biomolecules, EVs may also be used as unique drug-delivery systems for drugs in a variety of diseases conditions [64]. EVs have already been used to encapsulate small molecules, nucleic acids, peptides, and proteins to treat different diseases, the majority of which are cancers [65]. Among anticancer agents, curcumin, doxorubicin, and paclitaxel are the top three drugs being investigated.…”

Section: Extracellular Vesicles As a Unique Drug Delivery System For mentioning

confidence: 99%

Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19

Kumar

Zhi

Mukherji

et al. 2020

Viruses

111

104

View full text Add to dashboard Cite

In January 2020, Chinese health agencies reported an outbreak of a novel coronavirus-2 (CoV-2) which can lead to severe acute respiratory syndrome (SARS). The virus, which belongs to the coronavirus family (SARS-CoV-2), was named coronavirus disease 2019 (COVID-19) and declared a pandemic by the World Health Organization (WHO). Full-length genome sequences of SARS-CoV-2 showed 79.6% sequence identity to SARS-CoV, with 96% identity to a bat coronavirus at the whole-genome level. COVID-19 has caused over 133,000 deaths and there are over 2 million total confirmed cases as of 15 April 2020. Current treatment plans are still under investigation due to a lack of understanding of COVID-19. One potential mechanism to slow disease progression is the use of antiviral drugs to either block the entry of the virus or interfere with viral replication and maturation. Currently, antiviral drugs, including chloroquine/hydroxychloroquine, remdesivir, and lopinavir/ritonavir, have shown effective inhibition of SARS-CoV-2 in vitro. Due to the high dose needed and narrow therapeutic window, many patients are experiencing severe side effects with the above drugs. Hence, repurposing these drugs with a proper formulation is needed to improve the safety and efficacy for COVID-19 treatment. Extracellular vesicles (EVs) are a family of natural carriers in the human body. They play a critical role in cell-to-cell communications. EVs can be used as unique drug carriers to deliver protease inhibitors to treat COVID-19. EVs may provide targeted delivery of protease inhibitors, with fewer systemic side effects. More importantly, EVs are eligible for major aseptic processing and can be upscaled for mass production. Currently, the FDA is facilitating applications to treat COVID-19, which provides a very good chance to use EVs to contribute in this combat.

show abstract

Section: Extracellular Vesicles As a Unique Drug Delivery System For mentioning

confidence: 99%

Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19

Kumar

Zhi

Mukherji

et al. 2020

Viruses

111

104

View full text Add to dashboard Cite

show abstract

“…Although it continues to be a first-line treatment, paclitaxel has a very high toxicity profile. Its nonspecific activity affects healthy dividing cells and other cells such as neurons, where intracellular transport processes are linked to the activity of microtubules [ 59 , 60 ].…”

Section: Conventional Treatmentsmentioning

confidence: 99%

“…Abraxane ® has shown excellent results in terms of paclitaxel solubility and required dose reduction and considerable increases in overall response rate (ORR) in combination with carboplatin [ 59 ]. In addition to this formulation, the use of extracellular vesicles (EVs) has recently shown promising results in the encapsulation of antitumor drugs [ 60 ]. This type of vesicles, which includes exosomes, microvesicles, and apoptotic bodies, has advantages in terms of biocompatibility, immunogenicity, and cytotoxicity.…”

Section: Conventional Treatmentsmentioning

confidence: 99%

“…Several studies indicate paclitaxel was delivered successfully to tumor cells via tumor and mesenchymal stem cell-derived exosomes [ 62 , 63 , 64 ]. Modifications of exosomes by incorporating signal peptides to their surface improve the biodistribution of the drug and hinder the development of drug resistance mechanisms [ 60 ].…”

Section: Conventional Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy

García-Fernández

Fornaguera

Borrós

2020

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.

show abstract

“…Passive loading refers to the transfer of drugs into maternal cells or the cultivation of maternal cells with drugs, where the exosomes produced by these maternal cells will contain the drugs. Active loading refers to the loading of drugs into exosomes using physical methods, such as ultrasound, electroporation, extrusion, and freeze-thaw techniques [18,19]. The drug loading e ciency using these physical operations varies, but generally, it results in a certain degree of damage to the exosome, thus affecting the integrity of the exosome structure and function.…”

Section: Introductionmentioning

confidence: 99%

Exosomes Derived from Nanocomplex-Loaded Macrophages for Targeted Delivery of Docetaxel and siPLK1 against Castrate-Resistance Prostate Cancer

Tai

Zhang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. As a class of naturally occurring nanoparticles with low immunogenicity and high biocompatibility, exosomes have become a promising drug carrier for cancer therapy. However, their clinical applications remain a challenge due to their unsuitable donors, low scalability, as well as insuﬃcient targeting ability. Here, we describe and validate a new strategy for drug loading into exosomes. We developed a folate-conjugated exosome (Co-Exo-FA) derived from nanocomplex-loaded Raw264.7 macrophages. This Co-Exo-FA containing docetaxel (DTX) and PLK1 siRNA (siPLK1) could be used for targeted therapy of castrate-resistance prostate cancer (CRPC).Results. Our results showed that Co-Exo-FA exhibited high stability, enhanced cancer targeting ability, and led to the suppression of tumor growth with reduced toxicity in vivo. Moreover, the delivery of siPLK1 and DTX using an exosome system effectively silenced the PLK1 gene and exhibited improved anticancer effects.Conclusion. Our results indicated that we managed to overcome major barriers to the efficient utility of exosomes and demonstrated the synergistic efficacy of siPLK1 and DTX in the treatment of CRPC, highlighting their potential value in therapeutic clinical applications.

show abstract

Extracellular vesicles in cancer nanomedicine

Cited by 75 publications

References 141 publications

Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19

Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19

Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy

Exosomes Derived from Nanocomplex-Loaded Macrophages for Targeted Delivery of Docetaxel and siPLK1 against Castrate-Resistance Prostate Cancer

Contact Info

Product

Resources

About